729 related articles for article (PubMed ID: 25351955)
21. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J
Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733
[TBL] [Abstract][Full Text] [Related]
22. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
[TBL] [Abstract][Full Text] [Related]
23. ERK5 is activated by oncogenic BRAF and promotes melanoma growth.
Tusa I; Gagliardi S; Tubita A; Pandolfi S; Urso C; Borgognoni L; Wang J; Deng X; Gray NS; Stecca B; Rovida E
Oncogene; 2018 May; 37(19):2601-2614. PubMed ID: 29483645
[TBL] [Abstract][Full Text] [Related]
24. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Herr R; Köhler M; Andrlová H; Weinberg F; Möller Y; Halbach S; Lutz L; Mastroianni J; Klose M; Bittermann N; Kowar S; Zeiser R; Olayioye MA; Lassmann S; Busch H; Boerries M; Brummer T
Cancer Res; 2015 Jan; 75(1):216-29. PubMed ID: 25381152
[TBL] [Abstract][Full Text] [Related]
25. A Combinatorial Strategy for Targeting
Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
[TBL] [Abstract][Full Text] [Related]
26. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV
Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559
[TBL] [Abstract][Full Text] [Related]
27. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
[TBL] [Abstract][Full Text] [Related]
28. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.
Rizos H; Menzies AM; Pupo GM; Carlino MS; Fung C; Hyman J; Haydu LE; Mijatov B; Becker TM; Boyd SC; Howle J; Saw R; Thompson JF; Kefford RF; Scolyer RA; Long GV
Clin Cancer Res; 2014 Apr; 20(7):1965-77. PubMed ID: 24463458
[TBL] [Abstract][Full Text] [Related]
29. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.
Chi M; Ye Y; Zhang XD; Chen J
Drug Des Devel Ther; 2014; 8():255-62. PubMed ID: 24600206
[TBL] [Abstract][Full Text] [Related]
30. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
31. BRAF
Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X
Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720.
Kamata T; Dankort D; Kang J; Giblett S; Pritchard CA; McMahon M; Leavitt AD
Mol Cancer Res; 2013 Dec; 11(12):1530-41. PubMed ID: 24152792
[TBL] [Abstract][Full Text] [Related]
33. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Liu C; Peng W; Xu C; Lou Y; Zhang M; Wargo JA; Chen JQ; Li HS; Watowich SS; Yang Y; Tompers Frederick D; Cooper ZA; Mbofung RM; Whittington M; Flaherty KT; Woodman SE; Davies MA; Radvanyi LG; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2013 Jan; 19(2):393-403. PubMed ID: 23204132
[TBL] [Abstract][Full Text] [Related]
34. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
Packer LM; East P; Reis-Filho JS; Marais R
Pigment Cell Melanoma Res; 2009 Dec; 22(6):785-98. PubMed ID: 19682280
[TBL] [Abstract][Full Text] [Related]
35. Copper Chelation Inhibits BRAF
Brady DC; Crowe MS; Greenberg DN; Counter CM
Cancer Res; 2017 Nov; 77(22):6240-6252. PubMed ID: 28986383
[TBL] [Abstract][Full Text] [Related]
36. Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line.
Inozume T; Tsunoda T; Morisaki T; Harada K; Shirasawa S; Kawamura T
J Dermatol; 2018 Dec; 45(12):1434-1439. PubMed ID: 30222203
[TBL] [Abstract][Full Text] [Related]
37. The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang HB; Pan Y; Liu S; Chung YR; Abdel-Wahab O; Merghoub T; Rossi M; Kudchadkar RR; Lawson DH; Khuri FR; Lonial S; Chen J
Mol Cell; 2018 Mar; 69(6):923-937.e8. PubMed ID: 29547721
[TBL] [Abstract][Full Text] [Related]
38. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
[TBL] [Abstract][Full Text] [Related]
39. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.
Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y
J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777
[TBL] [Abstract][Full Text] [Related]
40. Targeting BRAFV600E in an inducible murine model of melanoma.
Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU
Am J Pathol; 2012 Sep; 181(3):785-94. PubMed ID: 22796458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
